CRESCENT BIOPHARMA (CBIO) stock: insider trades, news & valuation
Net buyingShare price and insider trades
CRESCENT BIOPHARMA insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $30.6M and 7 sold $1.5M of CBIO stock on the open market.
Get emailed when insiders cluster-buy stocks like CBIO
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CBIO insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $12.4M | 1 | $286K | 9 |
| Q2 2026 | — | 0 | $1.2M | 7 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | $18.2M | 1 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 CRESCENT BIOPHARMA, INC. insiders reported open-market purchases totaling $30.6M, while 7 insiders reported sales totaling $1.5M. Among insiders with enough purchase history to measure, Peter Evan Harwin (Director) has the highest Insider Score at 15. 16 of 16 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 18SEC | Joshua T BrummCEO | Sell Plan | 7,837271,765 held (−3%) | $16.71 | $131K | -10.8% | — |
| Sep 18SEC | Jonathan McneillCOO, President | Sell Plan | 3,839134,588 held (−3%) | $16.71 | $64K | -10.8% | — |
| Sep 18SEC | Joshua T BrummCEO | Sell Plan | 1,610279,602 held (−1%) | $17.90 | $29K | -16.7% | — |
| Sep 18SEC | Jonathan McneillCOO, President | Sell Plan | 731138,427 held (−1%) | $17.90 | $13K | -16.7% | — |
| Sep 18SEC | Jan PinkasChief Scientific Officer | Sell Plan | 65821,581 held (−3%) | $17.90 | $12K | -16.7% | — |
| Sep 18SEC | Ellie Eunkyung ImChief Medical Officer | Sell Plan | 62321,446 held (−3%) | $17.90 | $11K | -16.7% | — |
| Sep 18SEC | Barbara Harlin BisphamSee Remarks | Sell Plan | 62018,710 held (−3%) | $17.90 | $11K | -16.7% | — |
| Sep 18SEC | Richard William ScalzoCFO | Sell Plan | 56819,730 held (−3%) | $17.90 | $10K | -16.7% | — |
| Sep 18SEC | Ryan LynchSee Remarks | Sell Plan | 24013,631 held (−2%) | $17.90 | $4K | -16.7% | — |
| Jul 20SEC | Fairmount Healthcare Fund Ii L.P.Director | Buy | 853,4503,601,316 held (+31%) | $14.50 | $12.4M | +2.8% | — |
| Jun 23SEC | Joshua T BrummCEO | Sell Plan | 42,305281,212 held (−13%) | $17.99 | $761K | -17.1% | — |
| Jun 23SEC | Jonathan McneillCOO, President | Sell Plan | 20,549139,158 held (−13%) | $17.99 | $370K | -17.1% | — |
| Jun 23SEC | Jan PinkasChief Scientific Officer | Sell Plan | 1,28822,239 held (−5%) | $17.99 | $23K | -17.1% | — |
| Jun 23SEC | Ellie Eunkyung ImChief Medical Officer | Sell Plan | 1,21922,069 held (−5%) | $17.99 | $22K | -17.1% | — |
| Jun 23SEC | Barbara Harlin BisphamSee Remarks | Sell Plan | 1,21819,330 held (−6%) | $17.99 | $22K | -17.1% | — |
| Jun 23SEC | Richard William ScalzoCFO | Sell Plan | 1,11220,298 held (−5%) | $17.99 | $20K | -17.1% | — |
| Jun 23SEC | Ryan LynchSee Remarks | Sell Plan | 46513,871 held (−3%) | $17.99 | $8K | -17.1% | — |
| Dec 8SEC | Peter Evan HarwinDirector | Buy | 1,360,0002,747,866 held (+98%) | $13.41 | $18.2M | +11.2% | 15 |
Insiders at CRESCENT BIOPHARMA, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Peter Evan HarwinDirector | $18.2M | — | Dec 8, 2025 | 15 |
| Fairmount Healthcare Fund Ii L.P.Director | $12.4M | — | Jul 20, 2026 | — |
| Joshua T BrummCEO | — | $921K | Sep 18, 2026 | — |
| Jonathan McneillCOO, President | — | $447K | Sep 18, 2026 | — |
| Jan PinkasChief Scientific Officer | — | $35K | Sep 18, 2026 | — |
| Ellie Eunkyung ImChief Medical Officer | — | $33K | Sep 18, 2026 | — |
| Barbara Harlin BisphamSee Remarks | — | $33K | Sep 18, 2026 | — |
| Richard William ScalzoCFO | — | $30K | Sep 18, 2026 | — |
| Ryan LynchSee Remarks | — | $13K | Sep 18, 2026 | — |
CBIO stock: common questions
Are CRESCENT BIOPHARMA, INC. insiders buying CBIO stock?
In the past 12 months, 2 insiders reported open-market purchases of CBIO worth $30.6M. The latest was Director Fairmount Healthcare Fund Ii L.P. bought $12.4M of CBIO at $14.50 — first open-market purchase in our records; raises the stake by 31%.
Are CRESCENT BIOPHARMA, INC. insiders selling CBIO stock?
7 insiders reported sales worth $1.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CBIO's 52-week range?
Over the past year CBIO has traded between $8.94 and $26.98. It last closed at $14.91 on Oct 9, 2026.